miRNA clusters as therapeutic targets for hormone-resistant breast cancer

References

• Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92.
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643.
   PubMed Web of Science ®Google Scholar
• Butt AJ, Sutherland RL, Musgrove EA. Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res. 2007;9(5):306.
   PubMed Web of Science ®Google Scholar
• Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014;14(1):26–38.
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003;86(3–5):225–230.
   PubMed Web of Science ®Google Scholar
• Folkerd EJ, Martin LA, Kendall A, et al. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J Steroid Biochem Mol Biol. 2006;102(1–5):250–255.
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942–2962.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30–38.
   PubMed Web of Science ®Google Scholar
• Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011;11(11):1641–1652.
   PubMed Web of Science ®Google Scholar
• Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125(1–2):13–22.
   PubMed Web of Science ®Google Scholar
• Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26(3):331–345.
   PubMed Web of Science ®Google Scholar
• Ponzone R, Mininanni P, Cassina E, et al. Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer. 2008;15(1):27–36.
   PubMed Web of Science ®Google Scholar
• Dunn BK, Cazzaniga M, DeCensi A. Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer. Breast. 2013;22(3):225–237.
   PubMed Web of Science ®Google Scholar
• Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole–of clinical importance? Br J Cancer. 2011;104(7):1059–1066.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.
   PubMed Web of Science ®Google Scholar
• Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172–1187.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110.
   PubMed Web of Science ®Google Scholar
• Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515–524.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Croce CM. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011;51:25–43.
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–179.
   PubMed Web of Science ®Google Scholar
• Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–355.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070.
   PubMed Web of Science ®Google Scholar
• Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8(10):R214.
   PubMed Web of Science ®Google Scholar
• Dvinge H, Git A, Gräf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378–382.
   PubMed Web of Science ®Google Scholar
• Bezman NA, Chakraborty T, Bender T, et al. miR-150 regulates the development of NK and iNKT cells. J Exp Med. 2011;208:2717–2731.
   PubMed Web of Science ®Google Scholar
• Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009;1792:497–505.
   PubMed Web of Science ®Google Scholar
• Xu WD, Lu MM, Pan HF, et al. Association of microRNA-146a with Autoimmune Diseases. Inflammation. 2012;35:1525–1529.
   PubMed Web of Science ®Google Scholar
• Andreopoulos B, Anastassiou D. Integrated analysis reveals hsa-miR-142 as a representative of a lymphocyte-specific gene expression and methylation signature. Cancer Inform. 2012;11:61–75.
   PubMedGoogle Scholar
• Peng X, Guo W, Liu T, et al. Identification of miRs-143 and −145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS ONE. 2011;6:e20341.
   PubMed Web of Science ®Google Scholar
• Li B, Han Q, Zhu Y, et al. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. Febs J. 2012;279:2393–2398.
   PubMed Web of Science ®Google Scholar
• Git A, Spiteri I, Blenkiron C, et al. PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes. Breast Cancer Res. 2008;10:R54.
   PubMed Web of Science ®Google Scholar
• Guo H, Hu X, Ge S, et al. Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. Int J Biochem Cell Biol. 2012;44:1465–1472.
   PubMed Web of Science ®Google Scholar
• Castellano L, Giamas G, Jacob J, et al. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA. 2009;106(37):15732–15737.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Horlings HM, Ten Hoeve JJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71:4443–4453.
   PubMed Web of Science ®Google Scholar
• Volinia S, Galasso M, Sana ME, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 2012;109(8):3024–3029.
   PubMed Web of Science ®Google Scholar
• Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA. 2013;110(18):7413–7417.
   PubMed Web of Science ®Google Scholar
• Klinge CM. miRNAs and estrogen action. Trends Endocrinol Metab. 2012;23(5):223–233.
   PubMed Web of Science ®Google Scholar
• Guttilla IK, Adams BD, White BA. ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab. 2012;23(2):73–82.
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Tryndyak VP, Montgomery B, et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle. 2007;6(16):2010–2018.
   PubMed Web of Science ®Google Scholar
• Bhat-Nakshatri P, Wang G, Collins NR, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009; 37(14): 4850–4861.
   PubMed Web of Science ®Google Scholar
• Cicatiello L, Mutarelli M, Grober OM, et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol. 2010; 176(5): 2113–2130.
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–1123.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Piovan C, Gasparini P, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 2013;9(3):e1003311.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe NS, Manavalan TT, Dougherty SM, et al. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009;37(8):2584–2595.
   PubMed Web of Science ®Google Scholar
• Hah N, Danko CG, Core L, et al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell. 2011;145(4):622–634.
   PubMed Web of Science ®Google Scholar
• Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101(4):673–683.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Natrajan R, Lambros MB, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011;47(1):138–150.
   PubMed Web of Science ®Google Scholar
• Hinkal GW, Grelier G, Puisieux A, et al. Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT. Br J Cancer. 2011;104(2):387–388.
   PubMed Web of Science ®Google Scholar
• Kwon SY, Lee JH, Kim B, et al. Complexity in Regulation of microRNA Machinery Components in Invasive Breast Carcinoma. Pathol Oncol Res. 2014;20(3):697–705.
   PubMed Web of Science ®Google Scholar
• Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology. 2009;150(1):14–23.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Fujiyama S, Ito S, et al. Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell. 2009;36(2):340–347.
   PubMed Web of Science ®Google Scholar
• Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses eralpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132–1147.
   PubMed Web of Science ®Google Scholar
• Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (Eralpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol. 2009;23(8):1215–1230.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283(45):31079–31086.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Gasparini P, Piovan C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010;102(10):706–721.
   PubMed Web of Science ®Google Scholar
• Guttilla IK, Phoenix KN, Hong X, et al. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat. 2012;132(1):75–85.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Deng C, Wang J, et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(1):69–80.
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Makela R, Ostling P, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28(24):3926–3936.
   PubMed Web of Science ®Google Scholar
• Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006;26(21):8191–8201.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467.
   PubMed Web of Science ®Google Scholar
• Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51(3):227–238.
   PubMed Web of Science ®Google Scholar
• Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897–29903.
   PubMed Web of Science ®Google Scholar
• Lu Y, Roy S, Nuovo G, et al. Anti-microRNA-222 (anti-miR-222) and −181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 2011;286(49):42292–42302.
   PubMed Web of Science ®Google Scholar
• Jiang L, He D, Yanh D, et al. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014;588(11):2009–2015.
   PubMed Web of Science ®Google Scholar
• Hiscox S, Jiang W, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118(2):290–301.
   PubMed Web of Science ®Google Scholar
• Creighton C, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820–13825.
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Wu H, Ru P, et al. MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene. 2011;30:822–831.
   PubMed Web of Science ®Google Scholar
• Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014;233(4):368–379.
   PubMed Web of Science ®Google Scholar
• Shi W, Gerster K, Alajez NM, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926–2937.
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Das PM, Spoelstra NS, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010;9:317.
   PubMed Web of Science ®Google Scholar
• Ward A, Balwierz A, Jd Z, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013;32(9):1173–1182.
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene. 2012;31(1):39–47.
   PubMed Web of Science ®Google Scholar
• Frasor J, Chang EC, Komm B, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006;66(14):7334–7340.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Deng C, Lu W, et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Mol Med. 2011;17(11–12):1233–1241.
   PubMed Web of Science ®Google Scholar
• Shi L, Dong B, Li Z, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 2009;27:3423–3429.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang X, Shen P, et al. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA. 2006;103:9063–9068.
   PubMed Web of Science ®Google Scholar
• Cittelly DM1, Das PM, Salvo VA, et al. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010;31(12):2049–2057.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–13949.
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271–1277.
   PubMed Web of Science ®Google Scholar
• Rodríguez-González FG, Sieuwerts AM, Smid M, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(1):43–51.
   PubMed Web of Science ®Google Scholar
• Hoppe R, Achinger-Kawecka J, Winter S, et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer. 2013;49(17):3598–3608.
   PubMed Web of Science ®Google Scholar
• Jansen MP, Reijm EA, Sieuwerts AM, et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 2012;133(3):937–947.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30(4):343–375.
   PubMed Web of Science ®Google Scholar
• Lønning PE, Eikesdal HP. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer. 2013;20(4):R183–201.
   PubMed Web of Science ®Google Scholar
• Beelen K, Zwart W, Linn SC. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol. 2012;9(9):529–541.
   PubMed Web of Science ®Google Scholar
• Masri S, Liu Z, Phung S, et al. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 2010;124(1):89–99.
   PubMed Web of Science ®Google Scholar
• Shibahara Y, Miki Y, Onodera Y, et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol. 2012;227(3):357–366.
   PubMed Web of Science ®Google Scholar
• Ghimenti C, Mello-Grand M, Grosso E, et al. Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Exp Ther Med. 2013;5(3):902–906.
   PubMed Web of Science ®Google Scholar
• Ciruelos E, Pascual T, Arroyo Vozmediano ML, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res. 2001;7(12 Suppl):4369s–4375s.
   PubMed Web of Science ®Google Scholar
• Howell A, Abram P. Clinical development of fulvestrant (“Faslodex”). Cancer Treat Rev. 2005;31(Suppl 2):S3–9.
   PubMed Web of Science ®Google Scholar
• Xin F, Li M, Balch C, et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 2009;25(4):430–434.
   PubMed Web of Science ®Google Scholar
• Rao X, Di Leva G, Li M, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30(9):1082–1097.
   PubMed Web of Science ®Google Scholar
• Nam S, Long X, Kwon C, et al. An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics. 2012;13:732.
   PubMed Web of Science ®Google Scholar
• Manavalan TT, Teng Y, Litchfield LM, et al. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 2013;8(4):e62334.
   PubMed Web of Science ®Google Scholar